Eye Disease Market Primed for Shake-up: Roche touts study data of experimental Antibody Faricimab

ZURICH: Swiss drugmaker Roche has touted data for a new drug against a blindness-causing eye disease that hits millions of older people, the latest sign this multi-billion-dollar market is primed for disruption.

Roche's experimental faricimab, a bispecific antibody, showed potential for extended durability in use against the disease neovascular age-related macular degeneration, it said in a statement.

Read Also: U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug